PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation

被引:1
|
作者
Toth, Stefan [1 ]
Olexa, Peter [1 ]
Hertelyova, Zdenka [2 ]
Stefanic, Peter [3 ]
Kopolovets, Ivan [3 ]
Berek, Peter [3 ]
Filip, Vladimir [4 ]
Chakravarty, Ryan [1 ]
Siroka, Monika [5 ]
Pella, Daniel [6 ,7 ]
机构
[1] Pavol Jozef Safarik Univ, Air Force Mil Hosp, Fac Med, Dept Gerontol & Geriatr, Murgasova 1, Kosice 04086, Slovakia
[2] Pavol Jozef Safarik Univ, Dept Expt Med, Fac Med, Trieda SNP 1, Kosice 04190, Slovakia
[3] East Slovak Inst Cardiovasc Dis, Dept Vasc Surg, Ondavska 8, Kosice 04011, Slovakia
[4] Pavol Jozef Safarik Univ, Louis Pasteur Univ Hosp, Dept Orthopaed & Traumatol Locomotory Apparat, Trieda SNP 1, Kosice 04190, Slovakia
[5] Pavol Jozef Safarik Univ, Fac Med, Dept Med & Clin Biochem, Trieda SNP 1, Kosice 04190, Slovakia
[6] Pavol Jozef Safarik Univ, Fac Med, Dept Cardiol 2, Ondavska 8, Kosice 04011, Slovakia
[7] East Slovak Inst Cardiovasc Dis, Ondavska 8, Kosice 04011, Slovakia
来源
OPEN CHEMISTRY | 2020年 / 18卷 / 01期
关键词
PCSK9; inflammation; atherosclerosis; plaque; initiation; INTIMA-MEDIA THICKNESS; PLASMA PCSK9; RISK; EVOLOCUMAB; STIFFNESS; DISEASE;
D O I
10.1515/chem-2020-0147
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of this study was to detect the concentrations of PCSK9 in various subclinical stages of atherosclerosis and to highlight its relationship with inflammation. One hundred and fifty-nine healthy patients were divided into three groups, based on the extent of atherosclerotic changes in the carotid artery: a group without identifiable atherosclerosis, cIMT(>)(75 parts per thousand) and an asymptomatic plaque group. The PCSK9 was measured by ELISA and hsCRP by the immunoturbidimetric method. Vascular changes were identified by a carotid ultrasound. PCSK9 was elevated, when comparing the healthy group with the cIMT(>75 parts per thousand) group; however, no significant increase was detected between cIMT(>75 parts per thousand) and the asymptomatic plaque group. A positive linear correlation of the PCSK9 concentration and atherosclerotic changes was found; however, after the re-analysis in each group, this correlation persisted only in the group with still normal values. Additionally, a significant linear correlation was found between the PCSK9 concentrations and lipid parameters. However, no significant association was found with hsCRP. PCSK9 was found to be elevated only in cIMT(>75 parts per thousand), but not in the later plaque stage. A linear correlation of PCSK9 values was detected only in the group with still reference values. Based on this fact, we assumed the direct linear role of PCSK9 in initiating atherosclerosis; however, in the later phases, the relationship, which highlights other risk factors such as inflammation, is not linear.
引用
收藏
页码:1011 / 1019
页数:9
相关论文
共 50 条
  • [21] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [22] Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes
    Agarwal, Heena
    Tinsley, Brea
    Sarecha, Amesh K.
    Ozcan, Lale
    CURRENT ATHEROSCLEROSIS REPORTS, 2023, 25 (12) : 931 - 937
  • [23] Meta-GWAS on PCSK9 concentrations reveals associations of novel loci outside the PCSK9 locus in White populations
    Kheirkhah, Azin
    Schachtl-Riess, Johanna Franziska
    Lamina, Claudia
    Di Maio, Silvia
    Koller, Adriana
    Schoenherr, Sebastian
    Coassin, Stefan
    Forer, Lukas
    Sekula, Peggy
    Gieger, Christian
    Peters, Annette
    Koettgen, Anna
    Eckardt, Kai-Uwe
    Kronenberg, Florian
    ATHEROSCLEROSIS, 2023, 386
  • [24] PCSK9 inhibition and inflammation: A narrative review
    Ruscica, Massimiliano
    Tokgozoglu, Lale
    Corsini, Alberto
    Sirtori, Cesare R.
    ATHEROSCLEROSIS, 2019, 288 : 146 - 155
  • [25] Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
    Tardif, Jean-Claude
    Rheaume, Eric
    Rhainds, David
    Dube, Marie-Pierre
    EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2782 - 2784
  • [26] Are there different responses to different PCSK9 inhibitors?
    Asenjo Mota, A.
    Caamano Selma, O.
    Sanchez-Aquino Gonzalez, R.
    HIPERTENSION Y RIESGO VASCULAR, 2020, 37 (01): : 42 - 44
  • [27] Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis
    Qiao, Meng-Qian
    Li, Yue
    Yang, Yu-Xin
    Pang, Chen-Xu
    Liu, Yi-Ting
    Bian, Cong
    Wang, Li
    Chen, Xiao-Fang
    Hong, Bin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 247
  • [28] Variants of PCSK9 Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans. The GEA Project
    Zamarron-Licona, Erasmo
    Rodriguez-Perez, Jose Manuel
    Posadas-Sanchez, Rosalinda
    Vargas-Alarcon, Gilberto
    Banos-Gonzalez, Manuel Alfonso
    Borgonio-Cuadra, Veronica Marusa
    Perez-Hernandez, Nonanzit
    DIAGNOSTICS, 2021, 11 (05)
  • [29] PCSK9: A new participant in lipophagy in regulating atherosclerosis?
    Xiao, Jun
    Deng, Yi-Min
    Liu, Xiang-Rui
    Cao, Jian-Ping
    Zhou, Min
    Tang, Ya-Ling
    Xiong, Wen-Hao
    Jiang, Zhi-Sheng
    Tang, Zhi-Han
    Liu, Lu-Shan
    CLINICA CHIMICA ACTA, 2019, 495 : 358 - 364
  • [30] The role of PCSK9 in inflammation, immunity, and autoimmune diseases
    Frostegard, Johan
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (01) : 67 - 74